Literature DB >> 17978814

The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane.

M Huls1, C D A Brown, A S Windass, R Sayer, J J M W van den Heuvel, S Heemskerk, F G M Russel, R Masereeuw.   

Abstract

The Breast Cancer Resistance Protein (BCRP/ABCG2) is a transporter restricting absorption and enhancing excretion of many compounds including anticancer drugs. This transporter is highly expressed in many tissues; however, in human kidney, only the mRNA was found in contrast to the mouse kidney, where the transporter is abundant. In bcrp/abcg2((-/-)) mice, the expression of two sterol transporter genes, abcg5 and abcg8, was strongly increased in the kidney, perhaps as a compensatory mechanism to upregulate efflux. We found using immunohistochemical analysis clear localization of BCRP/ABCG2 to the proximal tubule brush border membrane of the human kidney comparable to that of other ABC transporters such as P-glycoprotein/ABCB1, MRP2/ABCC2, and MRP4/ABCC4. Hoechst 33342 dye efflux from primary human proximal tubule cells was significantly reduced by the BCRP/ABCG2 inhibitors fumitremorgin C and nelfinavir. Our study shows that in addition to other apical ABC transporters, BCRP/ABCG2 may be important in renal drug excretion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17978814     DOI: 10.1038/sj.ki.5002645

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  90 in total

1.  Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2.

Authors:  Heather M Brechbuhl; Neal Gould; Remy Kachadourian; Wayne R Riekhof; Dennis R Voelker; Brian J Day
Journal:  J Biol Chem       Date:  2010-03-23       Impact factor: 5.157

2.  Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.

Authors:  Julian R Molina; Scott H Kaufmann; Joel M Reid; Stephen D Rubin; Marina Gálvez-Peralta; Robert Friedman; Karen S Flatten; Kevin M Koch; Tona M Gilmer; Robert J Mullin; Roxanne C Jewell; Sara J Felten; Sumithra Mandrekar; Alex A Adjei; Charles Erlichman
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 3.  Advances in predictive in vitro models of drug-induced nephrotoxicity.

Authors:  Joanne Y-C Soo; Jitske Jansen; Rosalinde Masereeuw; Melissa H Little
Journal:  Nat Rev Nephrol       Date:  2018-06       Impact factor: 28.314

4.  Differential expression of ABC transporters (MDR1, MRP1, BCRP) in developing human embryos.

Authors:  A Konieczna; B Erdösová; R Lichnovská; M Jandl; K Cížková; J Ehrmann
Journal:  J Mol Histol       Date:  2011-10-20       Impact factor: 2.611

5.  N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfer into milk.

Authors:  Lipeng Wang; Markos Leggas; Mamta Goswami; Philip E Empey; Patrick J McNamara
Journal:  Drug Metab Dispos       Date:  2008-09-17       Impact factor: 3.922

Review 6.  ABCG transporters and disease.

Authors:  Owen M Woodward; Anna Köttgen; Michael Köttgen
Journal:  FEBS J       Date:  2011-06-13       Impact factor: 5.542

Review 7.  An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus.

Authors:  Lyrialle W Han; Chunying Gao; Qingcheng Mao
Journal:  Expert Opin Drug Metab Toxicol       Date:  2018-08-03       Impact factor: 4.481

8.  Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.

Authors:  Evan D Kharasch; Alysa Walker; Dale Whittington; Christine Hoffer; Pamela Sheffels Bedynek
Journal:  Drug Alcohol Depend       Date:  2009-02-18       Impact factor: 4.492

9.  Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney disease.

Authors:  Hirofumi Yano; Yoshifuru Tamura; Kana Kobayashi; Masayuki Tanemoto; Shunya Uchida
Journal:  Clin Exp Nephrol       Date:  2013-04-13       Impact factor: 2.801

10.  What lies behind serum urate concentration? Insights from genetic and genomic studies.

Authors:  Kimiyoshi Ichida
Journal:  Genome Med       Date:  2009-12-29       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.